Infliximab treatment for refractory Kawasaki syndrome

• Published in: The Journal of pediatrics Vol. 146; no. 5; pp. 662 - 667
• Main Authors: Burns, Jane C., Mason, Wilbert H., Hauger, Sarmistha B., Janai, Hillel, Bastian, John F., Wohrley, Julie D., Balfour, Ian, Shen, Cynthia A., Michel, Edward D., Shulman, Stanford T., Melish, Marian E.
• Format: Journal Article
• Language: English
• Published: New York, NY Mosby, Inc 01.05.2005; Elsevier
• Subjects: Adolescent; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Antibodies, Monoclonal - therapeutic use; Antirheumatic Agents - therapeutic use; Aspirin - therapeutic use; Biological and medical sciences; Child; Child, Preschool; Female; Fever - drug therapy; General aspects; Humans; Immunoglobulins, Intravenous; Infant; Infliximab; Male; Medical sciences; Mucocutaneous Lymph Node Syndrome - drug therapy; Mucocutaneous Lymph Node Syndrome - physiopathology; Retrospective Studies; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis; Treatment Outcome; Tumor Necrosis Factor-alpha - antagonists & inhibitors; CRP; CAA; eNOS; KS; IVIG; TNF; Ig; ASA; Kawasaki syndrome; Pediatrics; Treatment resistance; Cardiovascular disease; Autoimmune disease; Monoclonal antibody; Vascular disease; Immunomodulator; Refractory; Vasculitis; Treatment; Infliximab; Anticytokine; Systemic disease; Immunosuppressive agent

To evaluate the use of tumor necrosis factor (TNF)-α blockade for treatment of patients with Kawasaki syndrome (KS) who fail to become afebrile or who experience persistent arthritis after treatment with intravenous gamma globulin (IVIG) and high-dose aspirin. Cases were retrospectively collected fr...